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Contribution of factors other than CFTR mutations, either genetics and/or 
environmental, clearly affect the CF phenotype. We investigated whether the 
association between different SNPs are related to a clinical status ha a cobort of 16 
atypical CF patients with a borderline, normal or low increased sweat test which 
CFTR gene were entirely sequenced. A total of 8 variants, were identified: $519G, 
I1366T, 296+28A>C~ R75Q, Q493X, V562I, R668C, A 1C06E. The analy sis fccused 
on association of SNPs. 1) IVS 8 (TG)10T9 (GATI')6/(GATI')7 1001+11C>T and 
T854T, Q1463Q, is observed in 3 patients presenting sinusitis which 2 have mild 
pulmonary disease and one is also carrier of S 519G, G576A. The M470V frequently 
reported ha sinusitis is not present. 2) at homozygous late (TG)11T7 V470 is 
observed in 6 patients: 3 associated homozygous variant 405+46G>T which 2 had 
nasal polyposis (1 mild lung disease, R75Q variant, 1 dimlhcea, T1299T), mad 1 is 
PI with growth retardation. 3 patients had mild lung disease: 2 DBE, and 1 patient 
2752 15C>G. 3) among 3 other cases of nasal polyposis: twin sisters carried 
(TG)11T7 V470 P1290P Q1463Q, 3041 71G>C mad G576A, I1366T at 
heterozygous state, whereas 1 severe polyposis associated a complexe genotype 
(Q493X, V562I, AICO6E) with (TG)11T5 (TG)10T7 M470 and homozygous 
T854TQ1463Q. 4) among 3 PI patients, 2 associated moderate lung features, 
(TG)11T7 V470 G576A T854T Q1463Q a) 875+40A>G, (TG)11T5, b) R668C, 
(TG)10TT, 1 failure to thrive had (TG)12T7 M470 T854T Q1463Q, 296+28 A>G 
and (GATI')6. A greater series of atypical CF would be necessary to confirm this 
genotype/phenotype correlation. 
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Aims: Authors present the occurrence of clinical signs ha cot~celation with the CFI'R 
genotype. 
Methods: CF patients were matched on according enotype; 33pts: dF508/severe 
(G542X,R553X,CFI'RdeI21,N1303K) group A, 15 pts: dF508/mild (R347P,3849+ 
10kb) group B; 92 pts. dF508/dF508 group C. 
Results: A B C: Mean age was 10.6 17.5 13.8 years. Mean age at diagnosis was 
18.6 114.1 14.8 months. Meconium illeus: 12.1% 0% 17.4%. The mean sweat 
chloride values: 97.1 76.9 102.1. Hypalbuminemia: 15% 0% 15.2%, CFRDM: 
15% 0% 10.9%, rectal prolaps: 18.2% 0% 13%. Atopy: 3% 46.7% 9.7%, nasal 
polyposis 15.2% 33.3% 16.3%. FVC 74.7% 81.4% 79.2%; FEVI:  84.1% 72.3% 
74.9% pred. values; chronic colonisation with Pseudomonas 51.1% 54.5% 60%; 
Burkholderie 20.6% 30.3% 26.7%.Pancreatic elastase: 145.9 519.3 19.4 ggJg. 
Conclusions: Milder CF phenotype was ha group B. 
This study was supported by Association Mucoviscidose "ABCF proteins". 
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A procedure for full sequencing of all exons (with adjacent intr onic sequences) and 
of the 5' flanking region of CF IR  gene was optimized, in a 96 well format from 
initial PCR amplification to final sequence analysis. This method allowed the 
identification of two novel causing disease mutations of CFTR in exon 20. The 
G1247R(G ~'C) mutation was found in a CF subject showing anomalous genetic 
characterization by PCPUOLA/SCS assay (Celera Diagnostics). This subject 
appeared homozygous for W1282X mutation, although parents' allelic segregation 
showed that the W1282X mutation was present in heter ozigosity in the mother but 
absent in the father. Cycle sequencing (Applied Biosystems) of exon 20 showed that 
this subject was compound heterozygous W1282XAG1247R(G ~'C), this last 
mutation being carried by the father. The aminoacidic substitution G1247R has 
already been described as a disease causing CFFR mutation originated by 
nucleotidic substitution 3871G ~'A; in this case, instead, it originates from a 
3871G ~'C nucleotidic substitution. The anomalous genetic characterization by 
PCPUOLAdSCS is probably due to an interference of this mutation with the OLA 
probes. The G1244R mutation was found in a CF subject, with uncettain diagnosis, 
escaped to neonatal screening but showing some CF like symptoms mad previously 
characterized as heterozygous for the 3849+10Kb(C ~'T) mutation. The G1244R 
mutation is lccalized in a mutational hotspot where G1244V mad G1244E have 
akeady been described as disease causing mutations. Full sequencing of the CFTR 
gene appears as a high sensitivity protocol for detection of CFFR mutations. 
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Screening for large CFTR rearrangements should be considered in 
the diagnostic strategy for cystic f ibrosis in fetuses with bowel 
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Oys'tic fibrosis (CF) is reco~aized in 3% cases of fetal bowel anomalies ha France, 
the risk being higher when hyperechogenic bowel is associated with loop dilation 
and/or absence of gallbladder. Recommended investigations thus include screening 
for frequent CF mutations, in addition to fetal karyotyping and screening for 
infectious disease. When a frequent CF mutation is found in the fetus, the increased 
risk of CF justifies an in depth study of the second allele. We analyse sequentially 
the 27 exons mad also search for large rearrangements by semi quantitative 
fluorescent multiplex PCR, a recently developed assay which led to recognize about 
20% of previously unidentified alleles in CF patients. We here describe two cases 
of multiple fetal bowel anomalies with heterozygosity for a frequent mutation. 
Sequential nalysis of the 27 exons were negative. Screening for rearrangements led
to detect a new deletion of exons 2 6b and a deletion of exons 22,23, respectively, 
and to establish the diagnosis of CF. These cases, added to one previously described 
with a fetus homozygous for a deletion of exon 19, illustrate the need to include a 
quantitative t st ha the dia~aostic strategy for CF ha fetuses with bowel anomalies. 
Moreover, the method is rapid and sensitive enough to detect micro 
deletions/insertions. When applied after testing for frequent mutations, it increases 
the mutation detection rate of 4.5% in our population of CF patients, thus being the 
method of choice for 2 rd line screening, especially in emergency cases. 
